A Phase 3 interventional study of Ruxolitinib and Ruxolitinib Placebo in Myelofibrosis With High Molecular Risk Mutations, sponsored by Novartis Pharmaceuticals. Terminated at 110 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 22nd largest by enrollment, is one of 5 that started in 2016, is one of 6 in phase 3, and was the 26th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 27 · Phase 3 6 · Phase 4 4
First in 2007; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 45 across the 50 interventional studies. Of the 32 that completed or were terminated, 23 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
24 studies in Primary Myelofibrosis by Novartis: 1 open now, 4 under way, 2 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 24 studies in Primary Myelofibrosis by Novartis, this one is the 14th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2016, is one of 7 in phase 3, and was the 15th registered.
Novartis’s Primary Myelofibrosis studies by the year they started, since 2001.
6 of the studies testing ruxolitinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT06345495M.D. Anderson Cancer CenterHigh Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | 2027-01-01 |
| NCT05371964Geron CorporationA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | 2027-02 |
| NCT03069326Memorial Sloan Kettering Cancer CenterA Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, from their registry updates:
Among Novartis’s 24 in Primary Myelofibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Myelofibrosis patients with high molecular risk mutations have an intrinsically aggressive disease with increased risk of leukemic transformation and reduced overall survival. As there are no therapies currently established in the subset of high molecular risk patients with early myelofibrosis, the study aimed to evaluate ruxolitinib in this patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Two tablets of ruxolitinib 5 mg were administered orally twice per day.
Drug: Ruxolitinib
Two tablets of 5mg placebo were administered orally twice per day.
Drug: Ruxolitinib Placebo
5 mg tablet for oral use
Also known as: INC424
5 mg placebo tablet for oral use
Progression Free Survival (PFS-1)
Progression free survival (PFS-1) from date of randomization until the occurrence of any of the criteria for disease progression: * Progressive splenomegaly * Circulating peripheral blast counts \> 10% * Leukemic transformation * Hb \< 10g/dl with absolute decrease of at least 3 g/dl from baseline * White blood cell (WBC) counts \> 25 x 103/ μL * MF-7 score ≥ 30 * Death from any cause
Time frame: From randomization till disease progression (estimated to be assessed up 48 months)
Time to Primary Progression (TTP)
TTP is defined as time from randomization until disease progression as defined for PFS-1 excluding death as an event.
Time frame: From randomization till progression (estimated to be assessed up to 48 months)
Percentage Change in Spleen Volume From Baseline
Change in spleen volume (by MRI/CT) from baseline
Time frame: From baseline and assessed on 12 week intervals until end of treatment (EOT)
Percentage Change in Symptoms From Baseline Using MF-7
Percentage change from Baseline in MF-7 total symptom score and 7 individual symptoms at each visit was summarized with descriptive statistics. For this scale, symptoms range from 0 to 10 for the severity experienced within the past 24 hours, with 0 being for absence of symptoms and 10 for worst imaginable symptoms.
Time frame: From Baseline and assessed every 4 weeks until end of treatment
Number of Participants With Specific Subscale Scores (From Baseline) Using EQ-5D
EQ-ED5 profiles were summarized at baseline and at each scheduled assessment for each of the 5 dimensions separately (Mobility, self-care, usual activities, pain discomfort, anxiety/depression) Only participants with baseline score and at least one non-missing post-baseline score during the treatment period were included. Percentages were based on all these evaluable participants. The 5 scores for mobility, self-care, usual activities, pain/discomfort and anxiety/depression are all self-explanatory (eg "I have no problems walking" to "I am unable to walk"), except for the following overall health check, where 100 is the best of health, and 0 is the worst health.
Time frame: From Baseline and assessed every 4 weeks until end of treatment
Overall Survival
To evaluate the effect of ruxolitinib on overall survival
Time frame: Time from randomization to date of death due to any cause (estimated to be assessed up to 48 months).
Plasma Ruxolitinib Concentrations
Characterize pharmacokinetics (PK)by utilizing a population PK approach.
Time frame: Week 12, Wk 48
Progression Free Survival (PFS-2)
PFS-2 assessed by 25% increase over new baseline of PFS-1 in any of the following: ● Progressive splenomegaly ● 25 % increase in MF-7 score with absolute score ≥ 30
Time frame: From date of randomization until second disease progression or death, whichever comes first (estimated to be assessed up to 72 months)
Quality-adjusted Life Years From Baseline
EQ-5D-5L (EuroQol-5D-5L, is a standardized instrument for measuring health outcomes, is consists of a descriptive system and a visual analogue scale - scores can be summarized into a single index score that provides a simple measure of health for clinical and economic appraisal ) The EQ-5D-5L health states will be converted into index values (utilities) from which the QALY (Quality - adjusted life years) will be calculated. QALY will be summarized descriptively by treatment arm.
Time frame: Change from Baseline compared with scheduled study visits at the following intervals every 4 weeks up to week 24, every 8 weeks up to Week 48, every 12 weeks past Wk 48 until End of treatment and 30 day follow up visit
Time to First Progressive Splenomegaly (TTPS)
Time to first progressive splenomegaly as determined by spleen volume (by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT).
Time frame: From randomization until earliest time to progressive splenomegaly (estimated to be assessed up to 48 months)
Time to First Symptomatic Progression (TTSP)
Time to first symptomatic progression as determined by Myelofibrosis 7 Item Symptom Scale (MF-7)
Time frame: From randomization until symptomatic progression (MF-7)(estimated to be assessed up to 48 months)
Approximately 320 male or female adults (age 18 or over) with a confirmed diagnosis of MF were planned to be enrolled. The target population was not met due to early study termination. A total of 49 subjects were enrolled in the study, 25 in the ruxolitinib arm and 24 in the placebo arm.
| Milestone | Ruxolitinib (INC424) | Ruxolitinib Placebo |
|---|---|---|
| Started | 25 | 24 |
| Not treted wit study drug | 1 | 0 |
| Subjects followed for survival | 1 | 0 |
| Completed | 0 | 0 |
| Not completed | 25 | 24 |
| Withdrew: Study terminated by sponsor | 21 | 23 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Subject/guardian decision | 1 | 0 |
| Withdrew: Followed for survival | 1 | 0 |
Progression free survival (PFS-1) from date of randomization until the occurrence of any of the criteria for disease progression: * Progressive splenomegaly * Circulating peripheral blast counts \> 10% * Leukemic transformation * Hb \< 10g/dl with absolute decrease of at least 3 g/dl from baseline * White blood cell (WBC) counts \> 25 x 103/ μL * MF-7 score ≥ 30 * Death from any cause
No measurements were reported for this outcome.
TTP is defined as time from randomization until disease progression as defined for PFS-1 excluding death as an event.
No measurements were reported for this outcome.
Change in spleen volume (by MRI/CT) from baseline
| Percentage change from baseline | Ruxolitinib (INC424) | Ruxolitinib Placebo |
|---|---|---|
| Week 12 | -10.8 ± 24.45 | 9.1 ± 12.34 |
| Week 24 | -17.8 ± 18.83 | 17.6 ± 17.78 |
| Week 36 | -18.4 ± 31.62 | 32.5 ± 18.81 |
| Week 48 | -23.5 ± 10.57 | — |
| End of Treatment (EOT) | -11.6 ± 8.08 | 18.1 ± 18.58 |
Percentage change from Baseline in MF-7 total symptom score and 7 individual symptoms at each visit was summarized with descriptive statistics. For this scale, symptoms range from 0 to 10 for the severity experienced within the past 24 hours, with 0 being for absence of symptoms and 10 for worst imaginable symptoms.
| Percentage change in scores | Ruxolitinib (INC424) | Ruxolitinib Placebo |
|---|---|---|
| Total Score derived (TSD): Baseline (BL) | 6.6 ± 5.17 | 5.9 ± 5.56 |
| TSD change from baseline @ W12 | -0.3 ± 4.45 | 0.5 ± 6.08 |
| TSD change from baseline @ W24 | 0.5 ± 3.71 | -0.8 ± 6.44 |
| TSD change from baseline @ W48 | -0.3 ± 3.06 | — |
| TSD change from BL @ EOT | 1.1 ± 4.40 | 3.3 ± 9.53 |
| Tiredness: Baseline (BL) | 1.8 ± 1.45 | 1.5 ± 1.53 |
| Tiredness: change from baseline @ W12 | 0.1 ± 1.47 | 0.4 ± 1.27 |
| Tiredness: change from baseline @ W24 | -0.1 ± 0.76 | 1.1 ± 2.52 |
| Tiredness: change from baseline @ W48 | -0.3 ± 0.58 | — |
| Tiredness change from BL @ EOT | 0.8 ± 1.32 | 1.1 ± 2.28 |
| Filling up quickly when you eat (FUQWYE):BL | 1.0 ± 1.41 | 0.8 ± 1.27 |
| FUQWYE: change from BL @W12 | 0.1 ± 1.49 | -0.1 ± 2.09 |
| FUQWYE: change from BL @W24 | -0.2 ± 0.99 | 0.1 ± 1.17 |
| FUQWYE: change from BL @W48 | 0.7 ± 1.15 | — |
| FUQWYE: change from BL @ EOT | 0.2 ± 1.08 | 0.3 ± 2.29 |
| Abdominal discomfort (AD): BL | 0.7 ± 1.43 | 0.6 ± 1.10 |
| Abdominal discomfort change from BL @W12 | -0.1 ± 1.66 | -0.1 ± 0.85 |
| Abdominal discomfort change from BL @W24 | 0.0 ± 1.15 | -0.3 ± 0.71 |
| Abdominal discomfort change from BL @W48 | 0.0 ± 0.00 | — |
| AD: change from BL @ EOT | 0.1 ± 0.92 | 0.3 ± 1.40 |
| Night sweat (NS): Baseline (BL) | 0.7 ± 1.07 | 1.1 ± 1.45 |
| Night sweat change from BL @W12 | -0.1 ± 0.71 | -0.3 ± 1.29 |
| Night sweat change from BL @W24 | 0.5 ± 1.45 | -0.7 ± 1.41 |
| Night sweat change from BL @W48 | -0.3 ± 0.58 | — |
| Night Sweat: change from BL @ EOT | 0.0 ± 0.85 | 0.3 ± 2.12 |
| Itching (Pruritus):BL | 0.9 ± 1.42 | 0.6 ± 0.93 |
| Itching (Pruritus): change from BL @W12 | -0.3 ± 0.67 | 0.1 ± 1.45 |
| Itching (Pruritus): change from BL @W24 | 0.4 ± 0.77 | -0.3 ± 1.22 |
| Itching (Pruritus): change from BL @W48 | -1.0 ± 1.73 | — |
| Itching: change from BL @ EOT | 0.1 ± 1.03 | 0.4 ± 1.75 |
| Bone Pain: BL | 0.9 ± 1.35 | 0.9 ± 1.33 |
| Bone Pain: change from BL @W12 | -0.4 ± 1.01 | 0.3 ± 1.56 |
| Bone Pain: change from BL @W24 | -0.2 ± 1.17 | -0.8 ± 1.79 |
| Bone Pain: change from BL @W48 | 0.7 ± 1.15 | — |
| Bone Pain: change from BL @ EOT | 0.1 ± 0.96 | 0.6 ± 1.50 |
| Pain under ribs on left side (PUROLS): BL | 0.7 ± 1.18 | 0.4 ± 0.82 |
| PUROLS: change from BL @W12 | 0.4 ± 1.01 | 0.1 ± 0.76 |
| PUROLS: change from BL @W24 | 0.0 ± 0.41 | 0.1 ± 1.17 |
| PUROLS: change from BL @W48 | 0.0 ± 0.00 | — |
| PUROLS: change from BL @ EOT | -0.2 ± 0.68 | 0.3 ± 1.00 |
EQ-ED5 profiles were summarized at baseline and at each scheduled assessment for each of the 5 dimensions separately (Mobility, self-care, usual activities, pain discomfort, anxiety/depression) Only participants with baseline score and at least one non-missing post-baseline score during the treatment period were included. Percentages were based on all these evaluable participants. The 5 scores for mobility, self-care, usual activities, pain/discomfort and anxiety/depression are all self-explanatory (eg "I have no problems walking" to "I am unable to walk"), except for the following overall health check, where 100 is the best of health, and 0 is the worst health.
| Participants | Ruxolitinib (INC424) | Ruxolitinib Placebo |
|---|---|---|
| Mobility- Baseline: No problem | 17 | 18 |
| Mobility- Baseline: Slight problems | 4 | 5 |
| Mobility- Baseline: Moderate problems | 1 | 1 |
| Mobility- Baseline: Extreme problems | 1 | 0 |
| Mobility - Week 4:No prob. | 17 | 14 |
| Mobility - Week 4: Slight problems | 4 | 7 |
| Mobility - Week 4: Moderate problems | 1 | 2 |
| Mobility - Week 8: No problem | 17 | 15 |
| Mobility - Week 8: Slight problems | 3 | 6 |
| Mobility - Week 8: Moderate problems | 0 | 1 |
| Mobility - Week 12: No problem | 15 | 12 |
| Mobility - Week 12: Slight problems | 4 | 6 |
| Mobility - Week 12: Moderate problems | 0 | 2 |
| Mobility - Week 16: No problem | 12 | 10 |
| Mobility - Week 16: Slight problems | 2 | 7 |
| Mobility - Week 16: Moderate problems | 1 | 0 |
| Mobility - Week 20: No problem | 12 | 5 |
| Mobility - Week 20: Slight problems | 2 | 6 |
| Mobility - Week 24: No problem | 12 | 5 |
| Mobility - Week 24: Slight problems | 1 | 3 |
| Mobility - Week 24: Moderate problems | 0 | 1 |
| Mobility - Week 32: No problem | 8 | 1 |
| Mobility - Week 32: Slight problems | 0 | 1 |
| Mobility - Week 32: Moderate problems | 1 | 0 |
| Mobility - Week 40: No problem | 5 | 0 |
| Mobility - Week 40: Slight problems | 1 | 0 |
| Mobility - Week 48: No problem | 2 | 0 |
| Mobility - Week 48: Slight problems | 1 | 0 |
| Mobility - EOT: No problem | 11 | 12 |
| Mobility - EOT: Slight problems | 4 | 3 |
| Mobility - EOT: Moderate problems | 0 | 1 |
| Mobility- 30 day safety FU: No problem | 2 | 3 |
| Mobility- 30 day safety FU: Slight problems | 1 | 0 |
| Self-care - Baseline: No problem | 23 | 22 |
| Self-care - Baseline: Slight problems | 0 | 2 |
| Self-care - Week 4: No problem | 21 | 20 |
| Self-care - Week 4: Slight problems | 0 | 3 |
| Self-care - Week 4: Moderate problems | 1 | 0 |
| Self-care - Week 8: No problem | 19 | 21 |
| Self-care - Week 8: Slight problems | 1 | 1 |
| Self-care - Week 12: No problem | 17 | 19 |
| Self-care - Week 12: Slight problems | 1 | 1 |
| Self-care - Week 12: Moderate problems | 1 | 0 |
| Self-care - Week 16: No problem | 15 | 16 |
| Self-care - Week 16: Slight problems | 0 | 1 |
| Self-care - Week 20: No problem | 14 | 11 |
| Self-care - Week 24: No problem | 12 | 9 |
| Self-care - Week 24: Slight problems | 1 | 0 |
| Self-care - Week 32: No problem | 8 | 2 |
| Self-care - Week 32: Slight problems | 1 | 0 |
| Self-care - Week 40: No problem | 5 | 0 |
| Self-care - Week 40: Slight problems | 1 | 0 |
| Self-care - Week 48: No problem | 3 | 0 |
| Self-care - EOT: No problem | 14 | 15 |
| Self-care - EOT: Slight problems | 1 | 1 |
| Self-care - 30 day Safety FU: No problem | 3 | 3 |
| Usual activities -Baseline: No problem | 18 | 21 |
| Usual activities -Baseline: Slight problems | 4 | 3 |
| Usual activities - Baseline: Moderate problems | 1 | 0 |
| Usual activities - Week 4: No problem | 20 | 18 |
| Usual activities - Week 4: Slight problems | 1 | 4 |
| Usual activities - Week 4: Moderate problems | 1 | 0 |
| Usual activities - Week 4: Severe problems | 0 | 1 |
| Usual activities - Week 8: No problem | 20 | 18 |
| Usual activities - Week 8: Slight problems | 0 | 3 |
| Usual activities - Week 8: Moderate problems | 0 | 1 |
| Usual activities - Week 12: No problem | 16 | 16 |
| Usual activities - Week 12: Slight problems | 3 | 3 |
| Usual activities - Week 12: Moderate problems | 0 | 1 |
| Usual activities - Week 16: No problem | 13 | 14 |
| Usual activities - Week 16: Slight problems | 2 | 3 |
| Usual activities - Week 20: No problem | 13 | 9 |
| Usual activities - Week 20: Slight problems | 1 | 2 |
| Usual activities - Week 24: No problem | 12 | 9 |
| Usual activities - Week 24: Slight problems | 1 | 0 |
| Usual activities - Week 32: No problem | 8 | 2 |
| Usual activities - Week 32: Slight problems | 1 | 0 |
| Usual activities - Week 40: No problem | 5 | 0 |
| Usual activities - Week 40: Slight problems | 1 | 0 |
| Usual activities - Week 48: No problem | 3 | 0 |
| Usual activities - EOT: No problem | 12 | 13 |
| Usual activities -EOT: Slight problems | 3 | 3 |
| Usual activities - 30 day Safety FU: No problem | 2 | 3 |
| Usual activities - 30 say Safety FU: Slight probs | 1 | 0 |
| Pain/Discomfort - Baseline: No problem | 13 | 11 |
| Pain/Discomfort - Baseline: Slight problems | 8 | 12 |
| Pain/Discomfort - Baseline: Moderate problems | 2 | 1 |
| Pain/Discomfort - Week 4: No problem | 11 | 15 |
| Pain/Discomfort - Week 4: Slight problems | 10 | 6 |
| Pain/Discomfort - Week 4: Moderate problems | 1 | 2 |
| Pain/Discomfort - Week 8: No problem | 14 | 13 |
| Pain/Discomfort - Week 8: Slight problems | 5 | 7 |
| Pain/Discomfort - Week 8: Moderate problems | 1 | 2 |
| Pain/Discomfort - Week 12: No problem | 12 | 10 |
| Pain/Discomfort - Week 12: Slight problems | 7 | 6 |
| Pain/Discomfort - Week 12: Moderate problems | 0 | 4 |
| Pain/Discomfort - Week 16: No problem | 9 | 11 |
| Pain/Discomfort - WK16: Slight problems | 6 | 3 |
| Pain/Discomfort - WK16: Moderate problems | 0 | 3 |
| Pain/Discomfort - WK20: No problem | 8 | 8 |
| Pain/Discomfort - WK20: Slight problems | 6 | 3 |
| Pain/Discomfort - WK24: No problem | 9 | 7 |
| Pain/Discomfort - WK24: Slight problems | 4 | 2 |
| Pain/Discomfort - WK32: No problem | 7 | 2 |
| Pain/Discomfort - WK32: Slight problems | 2 | 0 |
| Pain/Discomfort - WK40: No problem | 4 | 0 |
| Pain/Discomfort - WK40: Slight problems | 2 | 0 |
| Pain/Discomfort - WK48: No problem | 3 | 0 |
| Pain/Discomfort - EOT: No problem | 8 | 10 |
| Pain/Discomfort - EOT: Slight problems | 7 | 3 |
| Pain/Discomfort - EOT: Moderate problems | 0 | 3 |
| Pain/Discomfort - 30 day Safety FU: No problem | 1 | 2 |
| Pain/Discomfort - 30 day safety FU: Slight probs | 2 | 0 |
| Pain/Discomfort - 30 day Safety FU: Moderate probs | 0 | 1 |
| Anxiety/Depression - Baseline: No problem | 14 | 18 |
| Anxiety/Depression - Baseline: Slight problems | 6 | 3 |
| Anxiety/Depression - Baseline: Moderate problems | 3 | 3 |
| Anxiety/Depression - WK4: No problem | 13 | 15 |
| Anxiety/Depression - WK4: Slight problems | 7 | 6 |
| Anxiety/Depression - WK4: Moderate problems | 2 | 2 |
| Anxiety/Depression - WK8: No problem | 11 | 16 |
| Anxiety/Depression - WK8: Slight problems | 8 | 2 |
| Anxiety/Depression - WK8: Moderate problems | 1 | 4 |
| Anxiety/Depression - WK12: No problem | 8 | 13 |
| Anxiety/Depression - WK12: Slight problems | 10 | 3 |
| Anxiety/Depression -WK12: Moderate problems | 1 | 4 |
| Anxiety/Depression - WK16: No problem | 10 | 10 |
| Anxiety/Depression - WK16: Slight problems | 5 | 5 |
| Anxiety/Depression - WK16: Moderate problems | 0 | 2 |
| Anxiety/Depression -WK20: No problem | 10 | 8 |
| Anxiety/Depression - WK20: Slight problems | 4 | 3 |
| Anxiety/Depression - WK24: No problem | 11 | 7 |
| Anxiety/Depression - WK24: Slight problems | 2 | 2 |
| Anxiety/Depression - WK32: No problem | 7 | 2 |
| Anxiety/Depression - WK32: Slight problems | 2 | 0 |
| Anxiety/Depression - WK40: No problem | 5 | 0 |
| Anxiety/Depression - WK40: Slight problems | 1 | 0 |
| Anxiety/Depression - WK48: No problem | 3 | 0 |
| Anxiety/Depression - EOT: No problem | 11 | 12 |
| Anxiety/Depression - EOT: Slight probs | 4 | 3 |
| Anxiety/Depression - EOT: Moderate probs | 0 | 1 |
| Anxiety/Depression - 30 day Safety FU: No probs | 2 | 2 |
| Anxiety/Depression-30 day Safety FU: Slight probs | 1 | 0 |
| Anxiety/Depression-30 day Safety FU: Severe probs | 0 | 1 |
To evaluate the effect of ruxolitinib on overall survival
No measurements were reported for this outcome.
Characterize pharmacokinetics (PK)by utilizing a population PK approach.
No measurements were reported for this outcome.
PFS-2 assessed by 25% increase over new baseline of PFS-1 in any of the following: ● Progressive splenomegaly ● 25 % increase in MF-7 score with absolute score ≥ 30
No measurements were reported for this outcome.
EQ-5D-5L (EuroQol-5D-5L, is a standardized instrument for measuring health outcomes, is consists of a descriptive system and a visual analogue scale - scores can be summarized into a single index score that provides a simple measure of health for clinical and economic appraisal ) The EQ-5D-5L health states will be converted into index values (utilities) from which the QALY (Quality - adjusted life years) will be calculated. QALY will be summarized descriptively by treatment arm.
No measurements were reported for this outcome.
Time to first progressive splenomegaly as determined by spleen volume (by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT).
No measurements were reported for this outcome.
Time to first symptomatic progression as determined by Myelofibrosis 7 Item Symptom Scale (MF-7)
No measurements were reported for this outcome.
Collected over Adverse events and serious adverse events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately up to approx. 55.1 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib (INC424) | 0/24 (0%) | 2/24 (8.3%) | 17/24 (70.8%) |
| Ruxolitinib Placebo | 0/24 (0%) | 1/24 (4.2%) | 11/24 (45.8%) |
| Event | Ruxolitinib (INC424) | Ruxolitinib Placebo |
|---|---|---|
| Tendon ruptureInjury, poisoning and procedural complications | 1/24 | 0/24 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/24 | 0/24 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/24 | 1/24 |
| Event | Ruxolitinib (INC424) | Ruxolitinib Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 7/24 | 6/24 |
| FatigueGeneral disorders | 3/24 | 4/24 |
| NasopharyngitisInfections and infestations | 4/24 | 0/24 |
| Upper respiratory tract infectionInfections and infestations | 3/24 | 0/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/24 | 0/24 |
| PruritusSkin and subcutaneous tissue disorders | 0/24 | 3/24 |
| HypertensionVascular disorders | 3/24 | 3/24 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/24 | 2/24 |
| PyrexiaGeneral disorders | 2/24 | 0/24 |
| Respiratory tract infectionInfections and infestations | 2/24 | 0/24 |
The Full Analysis Set (FAS) included all subjects who were randomized to a study treatment.
| Age, Continuous(Years) | Ruxolitinib (INC424) | Ruxolitinib Placebo | Total |
|---|---|---|---|
| Mean | 59.0 ± 14.23 | 67.4 ± 7.72 | 63.1 ± 12.17 |
| Sex: Female, Male(Participants) | Ruxolitinib (INC424) | Ruxolitinib Placebo | Total |
|---|---|---|---|
| Female | 12 | 7 | 19 |
| Male | 13 | 17 | 30 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib (INC424) | Ruxolitinib Placebo | Total |
|---|---|---|---|
| Caucasian | 19 | 23 | 42 |
| Asian | 4 | 1 | 5 |
| Other | 1 | 0 | 1 |
| Missing | 1 | 0 | 1 |
Showing the first 100 of 110 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Feb 2016 to primary completion in Oct 2017, 20 months.
Results were first posted in Aug 2019, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib